You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RAEB-t

Showing 1 - 25 of 8,020
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Prospective, Multicentre European Registry for Newly Diagnosed

Recruiting
  • Myelodysplastic Syndromes (MDS)
  • No interventions
  • Innsbruck, Austria
  • +17 more
Dec 28, 2020

MDS Over Time - Comparison of Treated vs Untreated Patients

Completed
  • Myelodysplastic Syndromes
    • Vienna, Austria
      Hanusch Krankenhaus, 3.Medizinische Abteilung
    Nov 21, 2022

    Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts Trial in Worldwide (rigosertib, Any approved or

    Terminated
    • Myelodysplastic Syndrome
    • +3 more
    • La Jolla, California
    • +157 more
    Sep 22, 2022

    Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis Trial in

    Completed
    • Myelodysplastic Syndrome RAEB-I or RAEB-II
    • +2 more
    • GM-CSF secreting leukemia vaccine
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Jan 28, 2022

    Changing Over Time of Ascorbic Acid After Chemotherapy

    Active, not recruiting
    • Leukemia (Both ALL and AML)
    • +2 more
    • blood withdrawn
    • Maastricht, Limburg, Netherlands
      MUMC+
    Sep 23, 2021

    Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in France, United States (oral

    Completed
    • Myelodysplastic Syndrome
    • +2 more
    • Gilbert, Arizona
    • +12 more
    Jun 15, 2021

    Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Duesseldorf (Lenalidomide, Azacitidine, Donor

    Completed
    • Leukemia, Myeloid, Acute
    • +2 more
    • Duesseldorf, NRW, Germany
      University Hospital Duesseldorf, Dept. of Hematology, Oncology a
    May 26, 2020

    Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • CAR-T Therapy
    • Hefei, Anhui, China
    • +7 more
    Jul 31, 2023

    Periodontal Diseases Trial in Turin (Decontamination of the pocket with local doxycycline, Decontamination of the pocket with

    Recruiting
    • Periodontal Diseases
    • Decontamination of the pocket with local doxycycline
    • Decontamination of the pocket with mechanical instrumentation
    • Turin, Italy
      CIR Dental School
    May 17, 2023

    Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

    Recruiting
    • Multiple Myeloma
    • APRIL-BAFF-Bicephali CAR-T cells
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 14, 2023

    Spinal Cord Injury Trial in Bronx (Natesto testosterone intranasal gel, Ayr Saline Nasal Gel)

    Not yet recruiting
    • Spinal Cord Injury
    • Natesto testosterone intranasal gel
    • Ayr Saline Nasal Gel
    • Bronx, New York
      James J. Peters VA Medical Center, Bronx, NY
    Nov 8, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • Cyclophosphamide (Non-IMP, Lymphodepletion)
    • +3 more
    • Ulm, Baden-Württemberg, Germany
    • +4 more
    Jul 24, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

    Recruiting
    • B Cell Malignancies
    • Universal CD19-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

    Recruiting
    • Neoplasms
    • +3 more
    • RD13-02 cell infusion
    • Wuhan, Hubei, China
      Union Hospital, Huazhong University of Science and Technology
    Jun 8, 2023

    Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

    Recruiting
    • Advanced Breast Cancer
    • +2 more
    • Trastuzumab Emtansine (T-DM1)
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Nov 5, 2023

    Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (Orca-T,

    Recruiting
    • Acute Myeloid Leukemia
    • +7 more
    • Orca-T
    • Standard-of-Care
    • Duarte, California
    • +13 more
    Jan 25, 2023

    Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

    Recruiting
    • Hematologic Malignancies
    • RD13-02 cell infusion
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Jun 26, 2023

    B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • CD19/CD22-bispecific CAR-T cells
    • Beijing, Beijing, China
      Liang Wang
    Oct 7, 2023

    Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)

    Recruiting
    • Neoplasms
    • +2 more
    • RD13-02 cell infusion
    • Hefei, Anhui, China
      The First Affiliated Hospital of University of Science and Techn
    Jun 5, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Brain Gliomas Trial in Suzhou (Allogenic B7H3 CAR-?dT cell)

    Recruiting
    • Brain Gliomas
    • Allogenic B7H3 CAR-γδT cell
    • Suzhou, Jiangsu, China
      Dushu Lake Hospital Affiliated to Soochow University
    Aug 25, 2023

    Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

    Recruiting
    • Metastatic Breast Cancer
    • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
    • Rome, Italy
      Fondazione Policlinico A. Gemelli - IRCCS
    Jun 22, 2023

    Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

    Recruiting
    • Neoplasms
    • +2 more
    • RD13-02 cell infusion
    • Xuzhou, Jiangsu, China
      Affiliated hospital of Xuzhou medical college
    Jun 7, 2023

    Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

    Active, not recruiting
    • Leukemia
    • Acute Lymphoblastic Leukemia
    • gene-modified T cells targeted
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Feb 1, 2023